- Home
- JAZZ vs BXSL Comparison
JAZZ vs BXSL Comparison
Compare JAZZ & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- BXSL
- Stock Information
- Founded
- JAZZ 2003
- BXSL 2018
- Country
- JAZZ Ireland
- BXSL United States
- Employees
- JAZZ N/A
- BXSL N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- BXSL Trusts Except Educational Religious and Charitable
- Sector
- JAZZ Health Care
- BXSL Finance
- Exchange
- JAZZ Nasdaq
- BXSL Nasdaq
- Market Cap
- JAZZ 7.3B
- BXSL 6.0B
- IPO Year
- JAZZ 2007
- BXSL N/A
- Fundamental
- Price
- JAZZ $121.18
- BXSL $32.57
- Analyst Decision
- JAZZ Buy
- BXSL Strong Buy
- Analyst Count
- JAZZ 14
- BXSL 9
- Target Price
- JAZZ $173.93
- BXSL $28.25
- AVG Volume (30 Days)
- JAZZ 567.6K
- BXSL 981.9K
- Earning Date
- JAZZ 02-26-2025
- BXSL 11-08-2023
- Dividend Yield
- JAZZ N/A
- BXSL 9.77%
- EPS Growth
- JAZZ 458.10
- BXSL N/A
- EPS
- JAZZ 7.04
- BXSL N/A
- Revenue
- JAZZ $3,992,712,000.00
- BXSL $491,357,000.00
- Revenue This Year
- JAZZ $7.51
- BXSL $195.77
- Revenue Next Year
- JAZZ $6.84
- BXSL $1.83
- P/E Ratio
- JAZZ $17.22
- BXSL N/A
- Revenue Growth
- JAZZ 5.23
- BXSL 27.36
- 52 Week Low
- JAZZ $99.06
- BXSL $23.82
- 52 Week High
- JAZZ $134.17
- BXSL $31.64
- Technical
- Relative Strength Index (RSI)
- JAZZ 46.66
- BXSL 55.68
- Support Level
- JAZZ $118.72
- BXSL $32.01
- Resistance Level
- JAZZ $124.66
- BXSL $32.25
- Average True Range (ATR)
- JAZZ 2.82
- BXSL 0.56
- MACD
- JAZZ -0.21
- BXSL -0.00
- Stochastic Oscillator
- JAZZ 31.62
- BXSL 58.82
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives through originated loans and other securities, including syndicated loans, of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, and unsecured and subordinated loans and other debt and equity securities.